Dr. Odumosu is the Chief Executive Officer of Zelira Therapeutics (ASX: ZLD, OTCQB: ZLDAF) and brings more than a decade of biopharmaceutical expertise in organization leadership, business development, scientific and clinical research, product development, regulatory approval, business operations, global commercialization and licensing including strategic alliance management. Dr. Odumosu is also a notable World Bank Institute Certified public health professional with global healthcare translational/clinical/epidemiological research and data management expertise. Prior to joining Zelira, he was the founding Chief Operating officer at Ilera Healthcare. Recently Dr. Odumosu was named to the board of the National Cannabis Roundtable, which promotes common sense federal regulation, tax equality and financial services reform and supports changing federal to acknowledge states rights to regulate and manage cannabis policy.
Dr. Odumosu earned his PhD in Biochemistry and a Master’s in Public Health-Epidemiology and Biostatistics from the Loma Linda University School of Medicine and School of Public Health, and a BS in Biology from Calvin College, Michigan.